Physician profile
Daniel J Feinstein
NPI 1922060045
$212,887.68
in general payments reported to CMS, 2019-2025
17 companies · $8,068 in 2025
The $8,068 reported for 2025 was more than what 94% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $23K · 2021: $22K · 2022: $35K · 2023: $50K · 2024: $26K · 2025: $8,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Consulting Fee: $11K · Travel and Lodging: $11K · Honoraria: $3,750 · Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,905.00 |
| Consulting Fee | $10,805.00 |
| Travel and Lodging | $10,676.13 |
| Honoraria | $3,750.00 |
| Food and Beverage | $1,019.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $181,077.56 | 2019-2025 | Biofire Respiratory Panel 2.1, Biofire Spotfire Respiratory (R) Panel, Filmarray Pneumonia Panel (Pneumo) |
| Fisher Scientific Company L.L.C. | $21,086.06 | 2022-2024 | Procalcitonin |
| La Jolla Pharmaceutical Company | $9,117.75 | 2019 | |
| Intuitive Surgical, INC. | $681.76 | 2024 | |
| Baxter Healthcare | $375.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.36 | 2021-2025 | Jardiance |
| Pfizer INC. | $81.07 | 2025 | |
| Abbott Laboratories | $78.95 | 2024 | Ensite |
| Astrazeneca Pharmaceuticals LP | $74.99 | 2019-2023 | Andexxa |
| Merck Sharp & Dohme LLC | $48.85 | 2022-2025 | Zerbaxa |
| Novo Nordisk INC | $39.07 | 2023-2024 | Rybelsus, Ozempic |
| Sunovion Pharmaceuticals INC. | $25.47 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $22.78 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.18 | 2022 | |
| Axsome Therapeutics, INC. | $17.88 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $16.27 | 2021 | |
| Quidel Corporation | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.